Unity Biotechnology, Inc.
unitybiotechnology.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed Apr 22, 2025. Its latest SEC filing is a 15-12G from Jan 2, 2026.
10-Q for Q1 FY2025, filed Apr 22, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops medicines designed to remove cells that contribute to diseases of aging, initially focusing on eye diseases.
10-K for FY2024, filed Mar 7, 2025We are a biotechnology company engaged in researching and developing therapeutics to slow, halt, or reverse diseases of aging. Our initial…View ↗
We are developing senolytic medicines to eliminate senescent cells from organs damaged by old age or damaged by diseases such as diabetes.…View ↗
We are targeting specific biological mechanisms implicated in diseases of aging. Our core therapeutic approach targets cellular senescence…View ↗
Who Were Their Customers?
Other companies license Unity's intellectual property under agreements with the company.
10-K for FY2024, filed Mar 7, 2025
How Were They Changing?
-
Sep 26, 2025
Unity filed a certificate of dissolution
The dissolution took effect, and the company closed its stock transfer books.
Sources
8-K, filed Sep 26, 2025
As previously reported, on June 27, 2025, the Board approved the Dissolution under the DGCL pursuant to the Plan of Dissolution. The…View ↗
-
Jun 30, 2025
Nasdaq moved to delist Unity as its CEO and CFO left
Unity said it would not appeal; the CEO and CFO ceased serving in connection with the planned wind-down.
Sources
8-K, filed Jun 30, 2025
Accordingly, Nasdaq, pursuant to its discretionary authority under Listing Rules 5101 and IM-5101-1, notified the Company that, unless the…View ↗
Loading...
